A database of FDA approved therapeutic peptides and proteins
This page displays user query in tabular form. |
1253 details |
Primary information | |
---|---|
ThPP ID | Th1035 |
Therapeutic Peptide/Protein Name | Glucagon recombinant |
Sequence | HSQGTFTSDYSKYLDSRRAQDFVQWLMNT view full sequnce in fasta |
Functional Classification | IV |
Molecular Weight | 3767.1 |
Chemical Formula | C165H249N49O51S1 |
Isoelectric Point | 9.52 |
Hydrophobicity | -1.197 |
Melting Point (℃) | N.A. |
Half Life | N.A. |
Description | Glucagon is a 29 residue peptide hormone, synthesized in a special non- pathogenic laboratory strain of Escherichia coli bacteria that has been genetically altered by the addition of the gene for glucagons. |
Indication/Disease | Used to treat severe hypoglycemia, also used in gastrointestinal imaging. |
Pharmacodynamics | Used in the treatment of hypoglycemia and in gastric imaging, glucagon increases blood glucose concentration and is used in the treatment of hypoglycemia. Glucagon acts only on liver glycogen, converting it to glucose through the release of insulin. It also relaxes the smooth muscles of the gastrointestinal tract. |
Mechanism of Action | Glucagon binds the glucagon receptor(G protein-coupled receptor located in the plasma membrane) which then initiates a dual signaling pathway using both adenylate cyclase activation and increased intracellular calcium. Adenylate cyclase manufactures cAMP (cyclic AMP), which activates protein kinase A (cAMP-dependent protein kinase). This enzyme, in turn, activates phosphorylase kinase, which, in turn, phosphorylates glycogen phosphorylase, converting into the active form called phosphorylase A. Phosphorylase A is the enzyme responsible for the release of glucose-1-phosphate from glycogen polymers. This yields glucose molecules to be released into the blood. Glucagon receptors are found in the liver, kidney, brain and pancreatic islet cells. The glucagon mediated signals lead to an increase in insulin excretion |
Toxicity | N.A. |
Metabolism | N.A. |
Absorption | N.A. |
Volume of Distribution | 0.25 L/kg |
Clearance | 13.5Â mL/min/kg [Adults with IV 1 mg] |
Categories | Hypoglycemic Agents |
Patents Number | N.A. |
Date of Issue | N.A. |
Date of Expiry | N.A. |
Drug Interaction | N.A. |
Target | N.A. |
Information of corresponding available drug in the market | |
Brand Name | N.A. |
Company | N.A. |
Brand Discription | N.A. |
Prescribed for | N.A. |
Chemical Name | N.A. |
Formulation | N.A. |
Physcial Appearnce | N.A. |
Route of Administration | N.A. |
Recommended Dosage | N.A. |
Contraindication | Pheochromocytoma |
Side Effects | N.A. |
Useful Link | http://www.drugs.com/pro/glucagen.html |
PubMed ID | 17462598, 17620721, 17623014, 17534934, 15817469 |
3-D Structure | Th1035 (View) or (Download) |